Projects

Corneal bioimpression for advanced surgical reparationCoordination Eric Gabison – UMR 976 Université Paris Cité – Fondation A. de Rothschild – CNRS – Inserm Key words Ulceration Cornea 3D printing Cell Therapy Tissue reconstruction Key figures Budget: 1,6 M€ Duration: 4 ans (2025 – 2029) Reference: ANR-24-PEBI-0001 Summary The aim of this project is to establish a…

Medication using specialized cell‐targeted lipid nanoparticle encapsulation in neuromuscular disordersCoordination Laurent Schaeffer – UMR 5261 Université Claude Bernard Lyon1 – CNRS – Inserm Pathophysiologie et génétique du neurone et du muscle (PGNM) Key words Non-viral vectors Lipid nanoparticle Gene delivery Antisens oligonucleotide Skeletal muscle Key figures Budget: 1.8 M€ Duration: 4 ans (2025 – 2029)…

Hybrid iPSC bioartificial liverCoordination Jean-Charles Duclos-Vallée – UMR 1193 Université Paris-Saclay – Inserm Physiopathogenèse et traitement des maladies du foie (HEPAREG) Key words Acute hepatic failure Hybrid extracorporeal liver system Hepatocytes Extracellular Vesicles Regenerative medicine Key figures Budget : 2.5 M€ Durée : 4 years (2025 – 2029) Référence : ANR-24-PEBI-0002 Summary The goal of…

Bioengineered stem cell-derived retinal cells and tissue for cell therapyCoordination Olivier GOUREAU – UMR S968 – UMR7210 SORBONNE UNIVERSITE- Institut de la Vision (INSERM UMRS968-CNRS UMR7210) Key words Retinal diseases Visual restoration Bioengineering Artificial intelligence Organoids Key figures Budget: 2.3 M€ Duration: 4 years (2025 – 2029) Reference : ANR-24-PEBI-0004 Summary In developed countries, the…

Personalised phage therapy against gram-negative multidrug resIstant organismsCoordination Jean-Damien Ricard – UMR 1137 Université Paris Cité – Inserm – Université Paris Nord Paris 13 – APHP Centre de recherche Infection, Antimicrobiens, Modélisation, Evolution (IAME) Key words Phagotherapy Phage Biobank Personalised medicine Machine learning prediction Digital holography Key figures Budget: 2.5 M€ Duration: 4 years (2025…

New Autonomously Replicating Non-Viral VectorsCoordination Philippe PASERO – UMR 9002 CNRS – Université de Montpellier Institut de Génétique Humaine (IGH) Key words Gene therapy Non-viral self-replicating plasmids AAV Vectors Bioproduction Key figures Budget: 2.5 M€ Duration: 4 years (2025 – 2029) Reference: ANR-24-PEBI-0006 Summary Gene therapy, which aims to correct diseases by modifying patients’ genetic…

ACCelerating Research for Early Development of Innovative Antibodies

Multidisciplinary approach to stimulate the bioproduction and engineering of Gram+ bacteria’s Extracellular Vesicles (EVs) for therapeutic applications to treat inflammation

Bioengineering of next-generation skin substitutes for cutaneous regeneration

Improving the whole chain of large scale AAV bioproduction through disruptive technologies

Development of biotherapies based on the local delivery of therapeutic RNAs by hybrid functionalized extracellular vesicles (EVs) for musculoskeletal regeneration

Development of breakthrough technologies in gene editing

Generation of iChondrocytes to regenerate articular cartilage

Genomic editing of stable universal pluripotent stem cells for allogeneic cell biotherapies

Innovative approaches for quality control to support the industrial deployment of future gene therapy products.

New generation of mRNA-based vaccines

From engineering of iPS-derived mesenchymal stromal cell-derived extracellular vesicles to clinical translation

B-cell genetic engineering for new therapeutic and vaccine modalities